Isolated hyperbilirubinemia as the manifestation of acute liver failure in a patient with acute myelogenous leukemia and COVID-19 infection


Submitted: 18 April 2021
Accepted: 22 May 2021
Published: 1 July 2021
Abstract Views: 879
PDF: 351
HTML: 31
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Nasrin Gholami Hematology Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic of.
  • Vahid Sheykhzadeh Amzajerdi Hematology Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic of.
  • Rahim Mehdioghli Hematology Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic of.
  • Hengameh Khadivi Heris Hematology Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic of.
  • Mona Jahandideh Kazempour Deparment of Microbiology, Faculty of Medical Genetic, Science and Research Islamic Azad University, Tehran, Iran, Islamic Republic of.

Acute liver failure is a rare but catastrophic syndrome. Liver function tests usually reveal cholestatic or hepatocellular pattern, but in this case, we report a previously undescribed manifestation of this condition as isolated hyperbilirubinemia. Our patient was a 50 years old male who was diagnosed with acute myelogenous leukemia (AML(M4)). The patient had no history of liver disease and had normal liver function tests at the time of admission. After chemotherapy treatment, the patient developed signs of acute liver failure and had a rapid demise. After further investigations, we found two possible causes. Firstly, liver involvement of acute myelogenous leukemia (AML) which after induction chemotherapy is a rare condition and has high mortality rates despite treatment. Secondly, acute liver injury due to COVID-19 infection.


Sobotka LA, Malli A, Chen W, Mumtaz K. Acute liver failure due to liver parenchymal infiltration with acute myelogenous leukaemia in a patient with myelodysplastic syndrome. BMJ Case Rep. 2018 Jun 28;2018:bcr2018224590. DOI: https://doi.org/10.1136/bcr-2018-224590

Goor Y, Goor O, Michalewitcz R, Cabili S. Acute myeloid leukemia presenting as obstructive jaundice. J Clin Gastroenterol. 2002 Apr;34(4):485-6. DOI: https://doi.org/10.1097/00004836-200204000-00023

Mathews E, Laurie T, O'Riordan K, Nabhan C. Liver involvement with acute myeloid leukemia. Case Rep Gastroenterol. 2008 Mar 14;2(1):121-4. DOI: https://doi.org/10.1159/000120756

Rajesh G, Sadasivan S, Hiran KR, Nandakumar R, Balakrishnan V. Acute myeloid leukemia presenting as obstructive jaundice. Indian J Gastroenterol. 2006 Mar-Apr;25(2):93-4.

Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, Fox AN, Zucker J, Verna EC. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. Hepatology. 2020 Sep;72(3):807-817. DOI: https://doi.org/10.1002/hep.31404

Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020 Jun;40(6):1278-1281. DOI: https://doi.org/10.1111/liv.14470

Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013 Dec 26;369(26):2525-34. DOI: https://doi.org/10.1056/NEJMra1208937

Gholami, N., Amzajerdi, V. S., Mehdioghli, R., Heris, H. K., & Kazempour, M. J. (2021). Isolated hyperbilirubinemia as the manifestation of acute liver failure in a patient with acute myelogenous leukemia and COVID-19 infection. European Journal of Translational Myology, 31(3). https://doi.org/10.4081/ejtm.2021.9817

Downloads

Download data is not yet available.

Citations